Landmark Study in The Lancet Oncology Shows Capecitabine (Xeloda) Combination Therapy Reduces Early Breast Cancer Recurrence
Posted by: DrugsNews on: 11 Nov, 2009
- In: Drugs News| News
- Comment!
Landmark Study in The Lancet Oncology Shows Capecitabine (Xeloda) Combination Therapy Reduces Early Breast Cancer Recurrence
- This is a third party press release. It will be issued by the
Finnish Breast Cancer Group on Wednesday 11 November 2009.
- FinXX, a Large, Phase III Randomised Study in Women With Early
Breast Cancer Shows that Adding Capecitabine…
Read more about Landmark Study in The Lancet Oncology Shows Capecitabine (Xeloda) Combination Therapy Reduces Early Breast Cancer Recurrence
| Indian Pharmacy! Looking for Generic Medications? Quality Drugs at affordable prices! Reliable Indian Pharmacy www.IndianPharmacy.org |
#1 Canadian Pharmacy Online! The Lowest Prices from Canadian Drugstore! Various payments, secure shopping, worldwide shipping! www.CanadianPharmacyLtd.org |
What are the Drugs-Review websites?
The Drugs-Review websites are NOT but will be your number one stop for all the latest news, comment and pharmaceutical industry information.
Related posts:
- Landmark Study In The Lancet Oncology Shows Capecitabine (Xeloda(R)) Combination Therapy Reduces Early Breast Cancer Recurrence
- GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival In Patients With Advanced Breast Cancer
- GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer
